Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with CAPOX and Modified Short-Course Radiation for MSS Rectal Cancer
NCT05972655Phase 2Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in rectal cancer, sponsored by Sir Run-Run Shaw Hospital. Started Aug 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05972655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972655.